Innoviva, Inc.·4

Mar 26, 7:19 PM ET

Zhen Marianne 4

4 · Innoviva, Inc. · Filed Mar 26, 2025

Insider Transaction Report

Form 4
Period: 2025-02-24
Zhen Marianne
Chief Accounting Officer
Transactions
  • Award

    Common Stock

    2025-02-24$18.08/sh+8,938$161,59951,312 total
  • Award

    Non-statutory Stock Option

    2025-02-24+30,30093,322 total
    Exercise: $18.08From: 2026-02-20Exp: 2034-03-05Common Stock (30,300 underlying)
Footnotes (2)
  • [F1]The Reporting Person was granted a time-vested restricted stock unit ("RSU"). Twenty-five percent of the shares subject to the RSU vest on February 20, 2026 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date, with accelerated vesting (i) in the event of a "change in control" (as defined in the Issuer's 2012 Equity Incentive Plan) in which the RSU is not assumed or replaced, or (ii) in the event that the Reporting Person experiences an "involuntary termination" of employment within 24 months following a "change in control," subject to an effective release of claims. The grant was approved by the Compensation Committee of the Board of Directors of the Company.
  • [F2]Twenty-five percent of the options vest on February 20, 2026 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date, with accelerated vesting (i) in the event of a "change in control" (as defined in the Issuer's 2012 Equity Incentive Plan) in which the options are not assumed or replaced, or (ii) in the event that the Reporting Person experiences an "involuntary termination" of employment within 24 months following a "change in control," subject to an effective release of claims. The grant was approved by the Compensation Committee of the Board of Directors of the Company.

Documents

1 file
  • 4
    form4.xmlPrimary